罗格列酮治疗2型糖尿病的疗效分析  

Effect of rosiglitazone (avandia) on type 2 diabetes mellitus with insulin resistance

作　　者：翁向群[1] 曾玉卿[1] 姜洪[1] 吴荔琼[1] 

机构地区：[1]南京军区福州总医院侨宾科,福建福州市350025

出　　处：《心血管康复医学杂志》2004年第3期237-239,共3页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：目的:观察罗格列酮(商品名文迪雅)对胰岛素抵抗的2型糖尿病患者的降糖疗效。方法:160例2型糖尿病曾应用胰岛素、其它类型降糖药或加强运动等基础治疗而血糖控制不理想的患者,加用罗格列酮4mg,每日1次;共观察24周,治疗前、后进行空腹、餐后2小时血糖及糖化血红蛋白测定。结果:罗格列酮治疗后患者空腹、餐后2小时血糖及糖化血红蛋白均有明显下降(P<0.01)。结论:罗格列酮能有效长期地控制血糖。Objective: To investigate the effect of rosiglitazone on type 2 diabetes mellitus with insulin resistance. Methods: A total of 160 patients with type 2 diabetes mellitus failed to control with metformin or insulin or sports. Rosiglitazone of 4 mg per day was given orally based on treatment of metformin and insulin adjusted the dosage according to level of blood glucose. Levels of fasting blood glucose, 2 hours blood glucose after diet and saccharify hemoglobin (HbAlc) were monitored before and during the period of Rosiglitazone treatment. Results: The levels of fasting glucose, 2 hours blood glucose after diet and HbAlc decreased in patients with rosiglitazone treatment, and the needs of biguanide metformin and insulin decreased at the end of 24 weeks of rosiglitazone treatment. Conclusion: Rosiglitazone can provide a long-term effect in controlling levels of blood glucose in patients with type 2 diabetes mellitus with insulin resistance.

关 键 词：罗格列酮 药物治疗 2型糖尿病 降糖药 血糖控制 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]